Hydromorphon-Hcl Glenmark (Hydromorphone Hydrochloride)

Hydromorphone binds with high affinity to µ‑opioid receptors in the brain and spinal cord. This activation blocks the transmission of pain signals, reduces the release of excitatory neurotransmitters, and alters the perception of pain, resulting in potent analgesic effects.

The appropriate dose is individualized and determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, renal and hepatic function, and other clinical factors. Dosage adjustments are made to achieve effective pain control while minimizing adverse effects.

Safety data for hydromorphone in pregnancy and lactation are limited. Because opioids can cross the placenta and be excreted in breast milk, the product is generally avoided unless the potential benefit justifies the risk. Pregnant or nursing patients should discuss alternatives with their healthcare provider.

To place an enquiry, visit the product page at gnhindia.com, enter the required quantity, and submit the request. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and import documentation.

Hydromorphone is roughly five to seven times more potent than morphine on a milligram‑per‑milligram basis, allowing lower doses for equivalent analgesia. Both act on µ‑opioid receptors, but hydromorphone has a shorter half‑life and may produce less histamine‑mediated itching. Choice between them depends on patient response, side‑effect profile, and clinical judgment.

Store the product at ambient temperature, preferably below 25 °C (77 °F). Keep it in the original packaging, protect it from moisture, direct sunlight, and excessive heat. Do not store in bathrooms or near kitchen appliances that generate steam.

The medication is supplied as an oral tablet and should be swallowed whole with a full glass of water. It may be taken with or without food, but consistent administration with respect to meals can help maintain steady drug levels. Patients should follow the exact dosing schedule prescribed by their clinician.

The most critical risks include respiratory depression, especially in opioid‑naïve individuals or when combined with other depressants; severe hypotension; development of physical dependence, tolerance, and addiction; and rare events such as anaphylaxis or adrenal insufficiency. Prompt medical attention is required if any signs of these serious reactions appear.

Patients with known hypersensitivity to hydromorphone or any component of the formulation should avoid it. It is also contraindicated in individuals with severe respiratory depression, acute or severe asthma, paralytic ileus, or uncontrolled severe head injury. Caution is advised for those with significant renal or hepatic impairment, and for patients with a history of substance misuse.